Navigation Links
Questcor to Report Third Quarter 2011 Earnings and Conduct Conference Call on October 25, 2011
Date:10/11/2011

ANAHEIM, Calif., Oct. 11, 2011 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today announced that it will release third quarter 2011 financial results on Tuesday, October 25, 2011 after the close of the U.S. financial markets.  The Company will host a conference call and slide presentation via webcast on Tuesday, October 25, 2011 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss results and highlights of the third quarter, as well as current corporate developments.  

Conference call details:Date:Tuesday, October 25, 2Time:4:30 p.m. ETDial-in (U.S.):877-941-1465Dial-in (International):480-629-9643Web cast:www.questcor.comTo access an audio replay of the call:

Replay (U.S.):800-406-7325Replay (International):303-590-303Replay Passcode:4480054About QuestcorQuestcor Pharmaceuticals, Inc. is a biopharmaceutical company whose primary product helps patients with serious, difficult-to-treat medical conditions.  Questcor's primary product is H.P. Acthar® Gel (repository corticotropin injection), an injectable drug that is approved by the FDA for the treatment of 19 indications.  Of these 19 indications, Questcor currently generates substantially all of its net sales from three indications: the treatment of acute exacerbations of multiple sclerosis in adults, the treatment of infantile spasms in children under two years of age and the treatment of nephrotic syndrome. Specifically with respect to nephrotic syndrome, the FDA has approved Acthar to "induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus."  Questcor is also exploring the possibility of developing markets for other on-label indications and pursuing FDA approval of additional indications not currently on the Acthar label where there is high unmet medical need.  Questcor also markets Doral(R) (quazepam), which is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. For more information, please visit www.questcor.com.


'/>"/>
SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Questcor Pharmaceuticals Announces Preliminary Operating Metrics for Third Quarter 2011
2. Questcor Pharmaceuticals to Present at the Jefferies Global Healthcare Conference on September 28, 2011
3. Questcor Provides Updated New Paid Prescription Trends
4. UPDATING and ADDING: Questcor Pharmaceuticals to Present at Upcoming Investor Conferences in September
5. Questcor Pharmaceuticals to Present at the Canaccord Genuity Growth Conference on August 11, 2011
6. Questcor to Report Second Quarter 2011 Earnings and Conduct Conference Call on July 26, 2011
7. Questcor Proxy Proposals All Approved at 2011 Shareholder Meeting
8. Questcor Discusses ISS Proxy Recommendations; Provides Business Update
9. Questcor to Report First Quarter 2011 Earnings and Conduct Conference Call on April 26, 2011
10. Questcor Pharmaceuticals Announces Preliminary Operating Metrics for First Quarter 2011
11. Questcor Pharmaceuticals to Present at the Needham Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... NEW YORK , April 19, 2017 The ... anticipated to showcase a healthy CAGR during the forecast period ... product type in the global digital mobile X-Ray devices market, ... 2,000 Mn in 2017, expanding at a CAGR of 7% ... create absolute $ opportunity of more than US$ 100 Mn ...
(Date:4/19/2017)... NEW YORK , April 19, 2017 /PRNewswire/ ... This report on the prostate cancer ... of the global market. Increasing prevalence of prostate ... as innovation in the development of new drugs ... hormone-refractory prostate cancer drug due to lesser side ...
(Date:4/19/2017)...  Sorrento Therapeutics, Inc. (NASDAQ: SRNE ... new treatments for cancer and other unmet medical ... announced underwritten public offering of 23,625,084 shares of ... of $2.00 per share, before deducting underwriting discounts ... Sorrento.  The net proceeds to Sorrento from this ...
Breaking Medicine Technology:
(Date:4/30/2017)... San Francisco, CA (PRWEB) , ... April 30, 2017 , ... ... Bay Area, is proud to announce an updated blog post on the continual issue ... are "too busy" to seek a second opinion before dental surgery, but this can ...
(Date:4/29/2017)... ... April 29, 2017 , ... Natural Family Planning ... observe the naturally occurring signs and symptoms of a woman's menstrual cycle. ... , Natural family planning and fertility are special interests of Dr. Bazger’s. She ...
(Date:4/29/2017)... UTAH (PRWEB) , ... April 29, 2017 , ... Phytomer ... region. As a Phytomer Account Manager, Smith’s role is to provide excellent ... brands that make up The Phytomer Group. Smith comes to Phytomer with a wealth ...
(Date:4/29/2017)... (PRWEB) , ... April 29, 2017 , ... More than ... so what are Americans doing in their leisure time that causes hearing loss? May ... habits that may be contributing to hearing loss, as well as schedule a hearing ...
(Date:4/28/2017)... , ... April 28, 2017 , ... An April 24th article on Yahoo! ... 180 pounds with the help of a weight loss surgery. The woman, declaring “I will ... that have been left following her dramatic weight loss. Dr. Feiz & Associates notes that, ...
Breaking Medicine News(10 mins):